Canadian employers expanding GLP-1 coverage for weight loss: survey

Buobe IA context · why it matters

Nearly two-fifths of Canadian employers now cover GLP-1 therapies for both diabetes and weight loss — This expansion may encourage more employees to manage their weight through medical interventions, potentially reducing healthcare costs in the long term.
Coverage has increased from 31 per cent in 2025 and just 17 per cent in 2024 — Employers are increasingly recognizing GLP-1 therapies as a valuable benefit, which could set a precedent for future health plan offerings.

Published by

on •1 min read

Nearly two-fifths (37 per cent) of Canadian employers cover glucagon-like peptide-1 therapies for both diabetes and weight loss, up from 31 per cent in 2025 and just 17 per cent in 2024, according to a new survey by the International Foundation of Employee Benefit Plans.

Benefits Canada News Benefits Health benefits GLP-1 drugs weight management weight loss diabetes care chronic disease prescription drugs drug plan management Canadian employers obesity health insurance drug costs HCSA

Learn more